This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Li, T.-S. Articles by Hamano, K. PubMed Articles by Li, T.-S. Articles by Hamano, K. Related Collections Other Treatment CV surgery: transplantation, ventricular assistance, cardiomyopathy

(Circulation. 2009;120:S255-S261.)
© 2009 American Heart Association, Inc.

Cell Transplantation and Tissue Regeneration

Identification of Risk Factors Related to Poor Angiogenic Potency of Bone Marrow Cells From Different Patients

Tao-Sheng Li, MD, PhD; Masayuki Kubo, PhD; Kazuhiro Ueda, MD, PhD; Masanori Murakami, MD, PhD; Mako Ohshima, PhD; Toshiro Kobayashi, MD, PhD; Toshiki Tanaka, MD, PhD; Bungo Shirasawa, MD, PhD; Akihito Mikamo, MD, PhD; Kimikazu Hamano, MD, PhD

From the Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Japan.

Correspondence to Tao-Sheng Li, MD, PhD, Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, Japan 755-8505. E-mail litaoshe{at}yamaguchi-u.ac.jp

Background— Therapeutic angiogenesis induced by the implantation of autologous bone marrow–derived cells has been used for the treatment of ischemic diseases. However, as the outcomes of cell implantation obviously vary among patients, it is essential to identify patients that would benefit the most from this treatment.

Methods and Results— We collected clinical and laboratory data from 25 patients scheduled to undergo sternotomy for various surgical procedures. Then, we aspirated bone marrow cells from the sternum during the operation and investigated the cell quality in vitro by cultivation, and their angiogenic potency in vivo using an ischemic limb model of mice. The angiogenic potency of bone marrow cells differed among patients. Aging, renal failure, anemia, and high serum levels of triglyceride, C-reactive protein, interleukin-6, and type I collagen cross-linked N-telopeptide (NTX) significantly correlated with poor angiogenic potency of bone marrow cells. We assigned scores to these risk factors, and found a strong correlation between the risk scores of patients and the angiogenic potency of their bone marrow cells (r=–0.883, P<0.001). These risk scores can predict the angiogenic potency of bone marrow cells for inducing therapeutic angiogenesis with an accuracy of 80%.

Conclusions— We have identified the risk factors related to poor angiogenic potency of bone marrow cells and developed a new scoring system to predict their angiogenic potency for the treatment of ischemic diseases. Our results may help select patients for this treatment in future clinical trials.

Key Words: bone marrow cells • angiogenesis • risk factor